Comparison of a Combination of Vosaroxin (VOS) and Intermediate-Dose Cytarabine (IDAC) with Idac for the Consolidation Therapy of Younger Patients with Favorable- and Intermediate-Risk Acute Myeloid Leukemia (AML) in First Complete Remission (CR): Preliminary Results of a Randomized Phase 2 R4-VOS Study of the French ALFA-Filo AML Intergroup

Norbert Vey,Sylvain Chantepie,Chantal Himberlin,Mathilde Hunault,Clémence Loiseau,Claude Preudhomme,Xavier Thomas,Amine Belhabri,Emmanuel Raffoux,Arnaud Pigneux,Christine Terré,Marc Bernard,Anne Banos,Karine Celli-Lebras,Claude Gardin,Corentin Orvain,Isabelle Luquet,Hervé Dombret,Martin Carré ,Jean‐François Brasme ,Émilie Lemasle ,Ariane Mineur ,Christian Récher ,Pierre Péterlin ,Éric Delabesse ,Romain Guièze ,Cécile Pautas ,Jean François Hamel

doi:10.1182/blood-2020-137032

Comparison of a Combination of Vosaroxin (VOS) and Intermediate-Dose Cytarabine (IDAC) with Idac for the Consolidation Therapy of Younger Patients with Favorable- and Intermediate-Risk Acute Myeloid Leukemia (AML) in First Complete Remission (CR): Preliminary Results of a Randomized Phase 2 R4-VOS Study of the French ALFA-Filo AML Intergroup

Norbert Vey, Sylvain Chantepie + Show 26 more

Open Access

https://doi.org/10.1182/blood-2020-137032

Copy DOI

Journal: Blood

Publication Date: Nov 5, 2020

Affiliation: Institute Paoli-Calmettes, Centre Hospitalier Universitaire de Caen, Université de Caen Normandie, Centre Hospitalier Universitaire de Reims, University of Reims Champagne-Ardenne, Hôpital Robert-Debré, University of Angers, Inserm, Versailles Saint-Quentin-en-Yvelines University, Centre Hospitalier Universitaire de Lille, Institut de Biologie de Lille, Hôpital Lyon Sud, Centre Léon Bérard, Hôpital Saint-Louis, Hôpital Cardiologique du Haut-Lévêque, Hôpital André Mignot, Assistance Publique – Hôpitaux de Paris, Université Sorbonne Paris Nord, Centre Hospitalier Universitaire d'Angers, University Cancer Institute Toulouse Oncopole, Université Paris Cité, Centre Hospitalier Universitaire de Grenoble, University of Bordeaux, Centre Hospitalier Universitaire de Toulouse, Hôtel-Dieu de Paris, Hôpitaux Universitaires Henri-Mondor

#Intermediate-Dose Cytarabine #Acute Myeloid Leukemia + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Comparison of a Combination of Vosaroxin (VOS) and Intermediate-Dose Cytarabine (IDAC) with Idac for the Consolidation Therapy of Younger Patients with Favorable- and Intermediate-Risk Acute Myeloid Leukemia (AML) in First Complete Remission (CR): Preliminary Results of a Randomized Phase 2 R4-VOS Study of the French ALFA-Filo AML Intergroup

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.